Tianyin Pharma announced SFDA approval for a diabetes drug, Gliclazide Tablets (80 mg formulation). Gliclazide is an oral treatment for type 2 diabetes, administered when diet and exercise are not enough to control blood glucose. Patients take one or two tablets before eating to increase the production of insulin. Tinayin Pharma hopes to launch Gliclazide in July. The company did not issue any revenue projections for its newest product. More details....

Stock Symbol: (AMEX: TPI)     Share this with colleagues: